Coronavirus Drug

India's Jubilant Life inks licensing agreement with Gilead to manufacture Remdesivir, a potential drug to treat COVID-19

Jubilant Life Sciences Ltd on Tuesday said it has entered into a non-exclusive licensing agreement with Gilead Sciences, Inc that will grant it the right to register, manufacture and sell the latter's investigational drug, remdesivir